Focused Ultrasound Stimulation as a Neuromodulatory Tool for Parkinson’s Disease:: A Scoping Review

Keng Siang Lee; Benjamin Clennell; Tom G. J. Steward; Andriana Gialeli; Oscar Cordero-Llana; Daniel J. Whitcomb

doi:10.3390/brainsci12020289

Focused Ultrasound Stimulation as a Neuromodulatory Tool for Parkinson’s Disease: A Scoping Review

Keng Siang Lee, Benjamin Clennell, Tom G. J. Steward, Andriana Gialeli, Oscar Cordero-Llana, Daniel J. Whitcomb

Research output: Contribution to journal › Article (Academic Journal) › peer-review

11 Citations (Scopus)

93 Downloads (Pure)

Abstract

Non-invasive focused ultrasound stimulation (FUS) is a non-ionising neuromodulatory technique that employs acoustic energy to acutely and reversibly modulate brain activity of deep-brain structures. It is currently being investigated as a potential novel treatment for Parkinson’s disease (PD). This scoping review was carried out to map available evidence pertaining to the provision of FUS as a PD neuromodulatory tool. In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews, a search was applied to Ovid MEDLINE, Embase, Web of Science and Cochrane Central Register of Controlled Trials on 13 January 2022, with no limits applied. In total, 11 studies were included: 8 were from China and 1 each from Belgium, South Korea and Taiwan. All 11 studies were preclinical (6 in vivo, 2 in vitro, 2 mix of in vivo and in vitro and 1 in silico). The preclinical evidence indicates that FUS is safe and has beneficial neuromodulatory effects on motor behaviour in PD. FUS appears to have a therapeutic role in influencing the disease processes of PD, and therefore holds great promise as an attractive and powerful neuromodulatory tool for PD. Though these initial studies are encouraging, further study to understand the underlying cellular and molecular mechanisms is required before FUS can be routinely used in PD.

Original language	English
Article number	289
Number of pages	21
Journal	Brain Sciences
Volume	12
Issue number	2
DOIs	https://doi.org/10.3390/brainsci12020289
Publication status	Published - 19 Feb 2022

Bibliographical note

Funding Information:
Funding: This work was supported in part by grant MR/N0137941/1 for the GW4 BIOMED MRC DTP, awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/UKRI, and Bristol Research into Alzheimer’s and Care for the Elderly (BRACE).

Funding Information:
This work was supported in part by grant MR/N0137941/1 for the GW4 BIOMED MRC DTP, awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/UKRI, and Bristol Research into Alzheimer?s and Care for the Elderly (BRACE).

Publisher Copyright:
Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

neuroscience
neuromodulation
Parkinson’s disease
scoping review
ultrasound

Access to Document

10.3390/brainsci12020289

Full-text PDF (final published version)
This is the final published version of the article (version of record). It first appeared online via MDPI at https://doi.org/10.3390/brainsci12020289 . Please refer to any applicable terms of use of the publisher.
Final published version, 1 MBLicence: CC BY

Handle.net

Persistent link

Cite this

@article{aa5926fc24904d7a9cb7e30d5d16d70c,

title = "Focused Ultrasound Stimulation as a Neuromodulatory Tool for Parkinson{\textquoteright}s Disease:: A Scoping Review",

abstract = "Non-invasive focused ultrasound stimulation (FUS) is a non-ionising neuromodulatory technique that employs acoustic energy to acutely and reversibly modulate brain activity of deep-brain structures. It is currently being investigated as a potential novel treatment for Parkinson{\textquoteright}s disease (PD). This scoping review was carried out to map available evidence pertaining to the provision of FUS as a PD neuromodulatory tool. In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews, a search was applied to Ovid MEDLINE, Embase, Web of Science and Cochrane Central Register of Controlled Trials on 13 January 2022, with no limits applied. In total, 11 studies were included: 8 were from China and 1 each from Belgium, South Korea and Taiwan. All 11 studies were preclinical (6 in vivo, 2 in vitro, 2 mix of in vivo and in vitro and 1 in silico). The preclinical evidence indicates that FUS is safe and has beneficial neuromodulatory effects on motor behaviour in PD. FUS appears to have a therapeutic role in influencing the disease processes of PD, and therefore holds great promise as an attractive and powerful neuromodulatory tool for PD. Though these initial studies are encouraging, further study to understand the underlying cellular and molecular mechanisms is required before FUS can be routinely used in PD.",

keywords = "neuroscience, neuromodulation, Parkinson{\textquoteright}s disease, scoping review, ultrasound",

author = "Lee, {Keng Siang} and Benjamin Clennell and Steward, {Tom G. J.} and Andriana Gialeli and Oscar Cordero-Llana and Whitcomb, {Daniel J.}",

note = "Funding Information: Funding: This work was supported in part by grant MR/N0137941/1 for the GW4 BIOMED MRC DTP, awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/UKRI, and Bristol Research into Alzheimer{\textquoteright}s and Care for the Elderly (BRACE). Funding Information: This work was supported in part by grant MR/N0137941/1 for the GW4 BIOMED MRC DTP, awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/UKRI, and Bristol Research into Alzheimer?s and Care for the Elderly (BRACE). Publisher Copyright: Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = feb,

day = "19",

doi = "10.3390/brainsci12020289",

language = "English",

volume = "12",

journal = "Brain Sciences",

issn = "2076-3425",

publisher = "MDPI AG",

number = "2",

}

TY - JOUR

T1 - Focused Ultrasound Stimulation as a Neuromodulatory Tool for Parkinson’s Disease:

T2 - A Scoping Review

AU - Lee, Keng Siang

AU - Clennell, Benjamin

AU - Steward, Tom G. J.

AU - Gialeli, Andriana

AU - Cordero-Llana, Oscar

AU - Whitcomb, Daniel J.

N1 - Funding Information: Funding: This work was supported in part by grant MR/N0137941/1 for the GW4 BIOMED MRC DTP, awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/UKRI, and Bristol Research into Alzheimer’s and Care for the Elderly (BRACE). Funding Information: This work was supported in part by grant MR/N0137941/1 for the GW4 BIOMED MRC DTP, awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/UKRI, and Bristol Research into Alzheimer?s and Care for the Elderly (BRACE). Publisher Copyright: Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2022/2/19

Y1 - 2022/2/19

N2 - Non-invasive focused ultrasound stimulation (FUS) is a non-ionising neuromodulatory technique that employs acoustic energy to acutely and reversibly modulate brain activity of deep-brain structures. It is currently being investigated as a potential novel treatment for Parkinson’s disease (PD). This scoping review was carried out to map available evidence pertaining to the provision of FUS as a PD neuromodulatory tool. In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews, a search was applied to Ovid MEDLINE, Embase, Web of Science and Cochrane Central Register of Controlled Trials on 13 January 2022, with no limits applied. In total, 11 studies were included: 8 were from China and 1 each from Belgium, South Korea and Taiwan. All 11 studies were preclinical (6 in vivo, 2 in vitro, 2 mix of in vivo and in vitro and 1 in silico). The preclinical evidence indicates that FUS is safe and has beneficial neuromodulatory effects on motor behaviour in PD. FUS appears to have a therapeutic role in influencing the disease processes of PD, and therefore holds great promise as an attractive and powerful neuromodulatory tool for PD. Though these initial studies are encouraging, further study to understand the underlying cellular and molecular mechanisms is required before FUS can be routinely used in PD.

AB - Non-invasive focused ultrasound stimulation (FUS) is a non-ionising neuromodulatory technique that employs acoustic energy to acutely and reversibly modulate brain activity of deep-brain structures. It is currently being investigated as a potential novel treatment for Parkinson’s disease (PD). This scoping review was carried out to map available evidence pertaining to the provision of FUS as a PD neuromodulatory tool. In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews, a search was applied to Ovid MEDLINE, Embase, Web of Science and Cochrane Central Register of Controlled Trials on 13 January 2022, with no limits applied. In total, 11 studies were included: 8 were from China and 1 each from Belgium, South Korea and Taiwan. All 11 studies were preclinical (6 in vivo, 2 in vitro, 2 mix of in vivo and in vitro and 1 in silico). The preclinical evidence indicates that FUS is safe and has beneficial neuromodulatory effects on motor behaviour in PD. FUS appears to have a therapeutic role in influencing the disease processes of PD, and therefore holds great promise as an attractive and powerful neuromodulatory tool for PD. Though these initial studies are encouraging, further study to understand the underlying cellular and molecular mechanisms is required before FUS can be routinely used in PD.

KW - neuroscience

KW - neuromodulation

KW - Parkinson’s disease

KW - scoping review

KW - ultrasound

U2 - 10.3390/brainsci12020289

DO - 10.3390/brainsci12020289

M3 - Article (Academic Journal)

C2 - 35204052

SN - 2076-3425

VL - 12

JO - Brain Sciences

JF - Brain Sciences

IS - 2

M1 - 289

ER -